{"id":"https://openalex.org/W2776946053","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.2575","title":"Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).","display_name":"Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).","publication_year":2017,"publication_date":"2017-05-20","ids":{"openalex":"https://openalex.org/W2776946053","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.2575","mag":"2776946053"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2017.35.15_suppl.2575","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.2575","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.2575","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046203056","display_name":"Stergios J. Moschos","orcid":"https://orcid.org/0000-0002-8943-0845","observed_orcids":["https://orcid.org/0000-0002-8943-0845"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stergios J. Moschos","raw_affiliation_strings":["University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC;","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064026461","display_name":"Shahneen Kaur Sandhu","orcid":"https://orcid.org/0000-0002-8660-4475","observed_orcids":["https://orcid.org/0000-0002-8660-4475"]},"institutions":[{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Shahneen Kaur Sandhu","raw_affiliation_strings":["Peter MacCallum Cancer Centre, Melbourne, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Centre, Melbourne, Australia;","institution_ids":["https://openalex.org/I2800555584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010628808","display_name":"Karl D. Lewis","orcid":"https://orcid.org/0000-0001-9893-0537","observed_orcids":["https://orcid.org/0000-0001-9893-0537"]},"institutions":[{"id":"https://openalex.org/I921990950","display_name":"University of Colorado Denver","ror":"https://ror.org/02hh7en24","country_code":"US","type":"education","lineage":["https://openalex.org/I921990950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karl D. Lewis","raw_affiliation_strings":["University of Colorado, Denver, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado, Denver, CO;","institution_ids":["https://openalex.org/I921990950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008479799","display_name":"Ryan Joseph Sullivan","orcid":"https://orcid.org/0000-0001-5344-6645","observed_orcids":["https://orcid.org/0000-0001-5344-6645"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan J. Sullivan","raw_affiliation_strings":["Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025067315","display_name":"Douglas Buckner Johnson","orcid":"https://orcid.org/0000-0002-6390-773X","observed_orcids":["https://orcid.org/0000-0002-6390-773X"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas Buckner Johnson","raw_affiliation_strings":["Vanderbilt University Ingram Cancer Center, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Ingram Cancer Center, Nashville, TN;","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100618235","display_name":"Yilong Zhang","orcid":"https://orcid.org/0000-0001-6750-7613","observed_orcids":["https://orcid.org/0000-0001-6750-7613"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yilong Zhang","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001183616","display_name":"Erik Rasmussen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erik Rasmussen","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079943316","display_name":"Haby Adel Henary","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haby A. Henary","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070576000","display_name":"Georgina Venetia Long","orcid":"https://orcid.org/0000-0001-8894-3545","observed_orcids":["https://orcid.org/0000-0001-8894-3545"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I4210118383","display_name":"Melanoma Institute Australia","ror":"https://ror.org/02jxrhq31","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I4210118383"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Georgina V. Long","raw_affiliation_strings":["Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia;","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I4210118383"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"35","issue":"15_suppl","first_page":"2575","last_page":"2575"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-cutaneous-melanoma","display_name":"metastatic cutaneous melanoma","score":0.8659999966621399},{"id":"https://openalex.org/keywords/wild-type-p53","display_name":"wild-type p53","score":0.9810000061988831},{"id":"https://openalex.org/keywords/trametinib","display_name":"trametinib","score":0.9679999947547913},{"id":"https://openalex.org/keywords/dabrafenib","display_name":"dabrafenib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/braf-v600-mutation","display_name":"BRAF V600 mutation","score":0.8740000128746033},{"id":"https://openalex.org/keywords/mapk-inhibitors","display_name":"MAPK inhibitors","score":0.8159999847412109},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8809999823570251},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9380000233650208},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7379999756813049},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8420000076293945},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8379999995231628},{"id":"https://openalex.org/keywords/gastrointestinal-toxicity","display_name":"gastrointestinal toxicity","score":0.5709999799728394}],"concepts":[{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.8776088953018188},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8366557359695435},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.7167871594429016},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6143738627433777},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.571615993976593},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5364269614219666},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.5171970129013062},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.500913143157959},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.48284512758255005},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4342647194862366},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.417500376701355},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.415073424577713},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.39771705865859985},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.34151774644851685},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.2410283386707306},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.18697312474250793},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.18008312582969666},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.12490054965019226},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.1195937991142273},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2017.35.15_suppl.2575","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.2575","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.2575","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4282009902","https://openalex.org/W2891237423","https://openalex.org/W2560597540","https://openalex.org/W2955077735","https://openalex.org/W2311386604","https://openalex.org/W2965547724","https://openalex.org/W4391805830","https://openalex.org/W3167044124","https://openalex.org/W2905409417","https://openalex.org/W2896124389"],"abstract_inverted_index":{"2575":[0],"Background:":[1],"Large":[2],"sequencing":[3],"studies":[4],"in":[5,70],"MCM":[6,89],"have":[7],"shown":[8],"a":[9,86],"TP53WT":[10,17,73,84],"incidence":[11],"of":[12,57,98,137,317,376],"approximately":[13],"80%.":[14],"In":[15,373],"preclinical":[16],"melanoma":[18],"models,":[19],"the":[20,41,135,198,250,294,303],"oral":[21],"p53-MDM2":[22],"inhibitor":[23],"AMG":[24,58,91,166,205,223,241,289,312,380],"232":[25,59,92,167,206,224,290,313,381],"exhibited":[26],"synergistic,":[27],"cytotoxic-type":[28],"antitumor":[29,53,405],"activity":[30,54],"when":[31],"combined":[32,382],"with":[33,72,82,306,378,383],"MAPK":[34],"inhibitors.":[35],"This":[36],"phase":[37],"1":[38,202],"study":[39],"assessed":[40],"toxicity":[42],"(CTCAE":[43],"4.03),":[44],"maximum":[45],"tolerated":[46],"dose":[47,78,189],"(MTD),":[48],"pharmacokinetics":[49],"(PK),":[50],"and":[51,63,116,232,267,314,319,349,403],"preliminary":[52,199],"(RECIST":[55],"1.1)":[56],"plus":[60,109],"trametinib":[61],"(T)":[62],"dabrafenib":[64],"(D)":[65],"(BRAFV600-mutant)":[66],"or":[67,106,125],"T":[68,111,126,320,386],"(BRAFV600-WT)":[69],"pts":[71,81,141,238,245,377],"MCM.":[74],"Methods:":[75],"Using":[76],"3+3":[77],"escalation":[79],"design,":[80],"advanced":[83],"(using":[85],"CLIA-approved":[87],"assay)":[88],"received":[90],"PO":[93,114,120],"QD":[94,115,129,395],"for":[95,222],"seven":[96],"days":[97],"each":[99],"3-week":[100],"cycle":[101],"(7/21)":[102],"at":[103,152,204,302],"120,":[104],"240,":[105],"480":[107],"mg":[108,113,119,128,169,175,208,214,394],"either":[110],"2":[112,127,154,163,184,346,350],"D":[117,318,384],"150":[118],"BID":[121],"(Arm":[122,130,275,331,342,352,365],"1;":[123],"BRAFV600-mutant)":[124],"2;":[131,276],"BRAFnonV600-mutant).":[132],"Results:":[133],"At":[134],"time":[136],"this":[138,374],"analysis,":[139],"21":[140,244,325],"(median":[142],"age,":[143],"58":[144],"y":[145],"[range":[146],"24\u201376];":[147],"male,":[148],"n":[149,157,192,333,344,354,367],"=":[150,158,171,177,193,210,216,230,235,257,261,265,270,334,345,355,368],"11;":[151],"least":[153],"systemic":[155],"treatments,":[156],"15)":[159],"were":[160,226,254],"treated.":[161],"Arm":[162,201],"enrolled":[164,203],"first:":[165],"120":[168,207],"(n":[170,176,209,215,229,234,256,260,264,269],"6),":[172],"then":[173,212],"240":[174,277],"6).":[178],"Due":[179],"to":[180,298,392],"chronic":[181],"grade":[182],"(G)":[183],"gastrointestinal":[185],"toxicity,":[186],"an":[187,399],"intermediate":[188],"(180":[190],"mg;":[191],"3)":[194],"was":[195,279,389],"determined":[196],"as":[197,300,358],"MTD.":[200],"4),":[211],"180":[213,393],"2).":[217],"The":[218,272],"most":[219,251],"common":[220,252],"reasons":[221],"withdrawal":[225],"disease":[227,341],"progression":[228],"8)":[231],"AEs":[233,248],"4);":[236],"6":[237,327,369],"remain":[239],"on":[240],"232.":[242],"All":[243],"had":[246,328,339,362],"treatment-related":[247],"(TRAEs);":[249],"TRAEs":[253],"nausea":[255],"18),":[258],"fatigue":[259],"17),":[262],"diarrhea":[263],"14),":[266],"vomiting":[268],"13).":[271],"only":[273],"DLT":[274],"mg)":[278],"G":[280],"3":[281],"pulmonary":[282],"embolism.":[283],"Preliminary":[284],"PK":[285,321,401],"analysis":[286,316],"suggests":[287],"that":[288,299],"exposure":[291],"(area":[292],"under":[293],"curve)":[295],"is":[296,322],"similar":[297],"monotherapy":[301],"same":[304],"dose,":[305],"no":[307],"apparent":[308],"drug-drug":[309],"interaction":[310],"between":[311],"T;":[315],"ongoing.":[323],"Of":[324],"pts,":[326],"partial":[329],"response":[330],"1/2,":[332,343,353,366],"4":[335],"[67%]/2":[336],"[13%]),":[337],"13":[338],"stable":[340],"[33%]/11":[347],"[73%]),":[348],"progressed":[351],"0/2":[356],"[13%])":[357],"best":[359],"response;":[360],"17":[361],"tumor":[363],"reduction":[364],"[100%]/11":[370],"[73%]).":[371],"Conclusions:":[372],"population":[375],"MCM,":[379],"and/or":[385],"during":[387],"DE":[388],"tolerable":[390],"up":[391],"7/21":[396],"days,":[397],"showing":[398],"acceptable":[400],"profile":[402],"early":[404],"activity.":[406],"Clinical":[407],"trial":[408],"information:":[409],"NCT02110355.":[410]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-01-05T00:00:00"}